Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AC-201 in Subjects with Gout
NCT02287818Phase 2Completed
- Sponsor
- TWi Biotechnology, Inc.
- Start
- Dec 2014
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in gout comparing Placebo with AC-201 (2 arms). Primary endpoint: Proportion of Subjects Achieving Serum Uric Acid Concentration <6.0 mg/dL at 8 weeks. Started Dec 2014; status: completed.
02
Drugs
AC-201CR
03
Conditions
gout
Beyond the preview
Go deeper on NCT02287818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02287818.